1.25 - Fundamentals of Psychedelic-Assisted Therapies

03/25/23 • 12 min

In this podcast, we will provide a brief overview of psychedelic-assisted therapy, including its therapeutic process and the psychedelic experience.

Support the podcast

Certificate in Psychedelic Assisted Therapies

Donate to Mind Medicine Australia

In this episode:

The definition of psychedelic-assisted therapy
The three phases of the therapeutic process
The importance of non-psychedelic elements in the therapy
Set and setting during the psychedelic experience
The effects of psychedelic compounds on brain activity and subjective experience (aka phenomenology)
The need for further research in the field of psychedelic-assisted therapy

Support this show http://supporter.acast.com/mind-medicine-australia.

Become a member at https://plus.acast.com/s/mind-medicine-australia.

Hosted on Acast. See acast.com/privacy for more information.

In this podcast, we will provide a brief overview of psychedelic-assisted therapy, including its therapeutic process and the psychedelic experience.

Support the podcast

Certificate in Psychedelic Assisted Therapies

Donate to Mind Medicine Australia

In this episode:

The definition of psychedelic-assisted therapy
The three phases of the therapeutic process
The importance of non-psychedelic elements in the therapy
Set and setting during the psychedelic experience
The effects of psychedelic compounds on brain activity and subjective experience (aka phenomenology)
The need for further research in the field of psychedelic-assisted therapy

Support this show http://supporter.acast.com/mind-medicine-australia.

Become a member at https://plus.acast.com/s/mind-medicine-australia.

Hosted on Acast. See acast.com/privacy for more information.

Previous Episode

1.24 - Next Steps for Psychedelic-Assisted Therapies in Australia

In this podcast, we discuss what the next steps are, following the TGA's decision to change the classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists.

Support the podcast

In this episode:

The mission of Mind Medicine in light of the rescheduling of psilocybin and MDMA for medical use in Australia effective July 1st, 2023.
The podcast will shift focus towards a more in-depth analysis of newly published research articles on psychedelics, as well as previous research
Mind Medicine Australia is a non-profit organization dedicated to increasing medical access and awareness of psychedelic-assisted therapies.
Psychedelics are chemical compounds that temporarily alter brain function resulting in an "altered state of consciousness."
Mind Medicine Australia aims to provide better treatment options for patients suffering from mental illness, with a focus on developing clinical implementation frameworks and therapist training protocols.
Starting July 1, 2023, authorized prescribers will be able to prescribe psilocybin and MDMA for patients with treatment-resistant depression and post-traumatic stress disorder.
Mind Medicine Australia is arranging for these medicines to be supplied through licensed pharmacists holding Schedule 8 permits.
Only specialized psychiatrists who meet certain qualifications will be able to prescribe psilocybin and MDMA.
Australia is the first nation in the world to reschedule these medicines for medical purposes.
Mind Medicine Australia has trained 240 medical professionals through its Certificate in Psychedelic-Assisted Therapies (CPAT) since 2021, and will shortly be launching dates for 2023 intakes.

Certificate in Psychedelic Assisted Therapies

Patient Support Fund (Donate)

Support this show http://supporter.acast.com/mind-medicine-australia.

Become a member at https://plus.acast.com/s/mind-medicine-australia.

Hosted on Acast. See acast.com/privacy for more information.

Next Episode

1.26 - Current Status of Psychedelics in Psychiatry: A Brief Review of Clinical Research by Treatment Condition

This podcast discusses the current state of research on the use of psychedelics in psychiatry, especially psilocybin, for the treatment of depression and other mental illnesses, including the precautions that must be taken before treatment, the standardized four-stage treatment model for depression, and the obstacles that must be overcome to use psychedelic therapy on a larger scale.

Current Status of Psychedelics in Psychiatry (D Nutt & R Cahart-Harris)

Support the podcast

Certificate in Psychedelic Assisted Therapies

Donate to Mind Medicine Australia

In this episode:

The podcast reviews the clinical research on the use of psychedelics in psychiatry, including the history of psychedelic research, recent developments, and the potential of psilocybin as a treatment for various mental illnesses.
Psilocybin may be useful in treating depression and has been shown to have antidepressant effects on people with resistant depression, anxiety, and depression symptoms caused by life-threatening cancer diagnoses, as well as in treating alcohol and tobacco dependence.
Certain precautions must be taken before treatment, such as assessing whether the patient is suitable for psychedelic therapy and stopping medications that block or attenuate the effects of the psychedelic.
Psychedelic therapy involves a standardized four-stage process for depression treatment, which includes assessment, preparation, experience, and integration.
One of the main obstacles to using psychedelic therapy on a larger scale is the current resource-intensive model, which requires high-quality training and practice.

Support this show http://supporter.acast.com/mind-medicine-australia.

Become a member at https://plus.acast.com/s/mind-medicine-australia.

Hosted on Acast. See acast.com/privacy for more information.